[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported that 5,462 shares of ResMed common stock were issued to him on 08/15/2025 as the result of performance-based restricted stock units (RSUs) granted on 11/20/2024. The filing shows the shares were earned when the company's compensation committee certified that the performance metrics were met; the RSUs have a vesting schedule of one-third each anniversary of the grant.

Following this issuance, Mr. Sandercock beneficially owns 88,745 shares. The reported transaction lists a price of $0, reflecting the settlement of vested RSUs rather than an open-market purchase, and the Form 4 is signed and dated 08/19/2025.

Insights

Financial Analyst

TL;DR: Routine executive compensation vesting realized 5,462 shares following certified performance metrics, modestly increasing insider stake.

This Form 4 documents the settlement of performance-based RSUs into 5,462 ResMed shares for the CFO after metrics were certified. Such settlements are common compensation outcomes and do not reflect market trading intent. The incremental change in beneficial ownership (to 88,745 shares) is notable for disclosure but is unlikely by itself to materially affect valuation or share supply. Investors should view this as alignment of management pay with pre-set targets, not a directional trading signal.

Corporate Governance Expert

TL;DR: Governance process followed: performance targets certified and RSUs vested under a scheduled plan.

The filing indicates that the compensation committee certified achievement of performance conditions tied to RSUs granted on 11/20/2024, triggering vesting on 08/15/2025. The one-third annual vesting schedule implies multi-year retention incentives. This demonstrates standard governance practice of linking pay to performance and using staggered vesting to promote retention. The disclosure is timely and file-signed on 08/19/2025, meeting Section 16 reporting expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/15/2025		A(1)		5,462	A	$0	88,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

	Brett Sandercock, Chief Financial Officer	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.